There is a growing and heterogeneous group of patients who need dental surgery due to diseases or accidents. RegenCura has developed a green, mesoporous scaffold material with superior osteogenic properties compared to other commercial products.
A wish to enable children to move and play even under advanced medical treatment was the starting point for Nil Medical. This mission has now led to their first product, Vestpack, that now is being tested in clinic.
We have developed a new class of orally highly active anti-cryptosporidium agents. The product would be the first efficient anti-cryptosporidium therapy on the animal health market.
Shades of Green, led by Daniel Pacurar of Boreal Orchards, is developing innovative approaches for sustainable and adaptive greening solutions both for urban environments and for restoring disturbed ecosystems. The aim is to create moss-coated solutions for outdoor and indoor spaces that are both functional and aesthetic.
Neores mission is to improve neonatal ventilation to save more preterm infants from death and comorbidities. Their work in this field has led to the development of rPAP, the first novel resuscitation system in more than 30 years.
NanoBio Select@ is developing novel highly sensitive detection devices with aims to improve immunoassay technologies.
Food security can no longer rest on a bedrock of wasteful, fossil fuel-based fertilizer that create the environmental risk of leaching into aquatic ecosystems and causing eutrophication. Cropcision offers a step-change enhancement in fertilizer efficiency.
Prostate cancer (PC) is a common and multifocal disease, with symptoms ranging from harmless to lethal. In Sweden, about 10000 new cases are diagnosed every year.
Triple-negative breast cancer, a hard-to-treat cancer subtype more common in young women, needs improved drugs to increase patient survival. Our innovation, a small molecule that targets G-quadruplex DNA structures, will selectively eradicate triple-negative breast cancer cells, and thereby improve treatment.
Recurrent aphthous ulcers (RAS) are mouth ulcers that can last for more than a week at each occasion and during that period patients often suffer and need sick leave. About 80% of all patient’s state that the pain from RAS is the main symptom. The innovative oral patch (MO45A) shields the ulcer giving instant pain relief and improves healing primarily through it´s extensive hygroscopic effect.
MetaCurUm Biotech is developing a novel antibody treatment for metastatic cancers. The company´s drug development program is focused on transforming growth factor-beta (TGFβ) driven cancers, with the aim to optimize the treatment paradigms in aggressive forms of cancer with high unmet medical need such as prostate, lung, kidney, and endometrial cancer.
Acne vulgaris affects more than 80 percent of people at some point in their life and frequently continues into adulthood. Recent data suggest that there are about 680 million people living with acne around the world. This case focuses on a novel approach to fighting acne without the hazards of antibiotic resistance development.
We are developing safe and resistance-breaking molecules that target an enzyme essential for nerve signaling in mosquitoes via a new mode of action. In contrast to current insecticides, we have designed our molecules to specifically target mosquitoes, without affecting other organisms.